Morphosys Ag (MOR) Gross Profit Margin starting from the fourth quarter 2023 to fourth quarter 2022, Profitability Trends and Ranking, Fundamental Ratios - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Gross Margin
• EBITDA Margin
• Operating Margin
• Net Margin
• Pre-Tax Margin
• Effective Tax Rate
• Free Cash Flow Margin
• Cash Flow Margin
Morphosys Ag  (NASDAQ: MOR)


Morphosys Ag's Gross Profit Margin by quarter

Trends, Rankings, Statistics


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

MOR Gross Profit Margin (Dec 31 2023)
Q4 		0
Q3 		0
Q2 		0
Q1 		(Dec 31 2022)
Q4
Y / Y Revenue Change -14.37 %
Seq. Revenue Change -
Revenue In Millions $266.87
Gross Profit Margin 75.51 %
Gross Profit Margin Total Ranking # 847
Gross Profit In Millions $201.52
Y / Y Gross Profit Change -21.65 %
Seq. Gross Profit Change -


Commenting fourth quarter 2023 Gross Profit Margin



Observing fourth quarter 2023 results within Major Pharmaceutical Preparations industry 71 other companies have achieved higher Gross Profit Margin. While Gross Profit Margin overall ranking has deteriorated relative to the three months before, from to 847.
Learn about Gross Margin
MOR's Gross Profit Margin fourth quarter 2023 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 72
Healthcare Sector # 139
Overall # 833

Gross Profit Margin Statistics
High Average Low
97.2 % 84.33 % 75.51 %
(Dec 31 2020)   (Dec 31 2023)


MOR Gross Income Trends • More of MOR's Profitabilty Ratios • MOR Stock Quotes and Charts


Other Gross Profit Margin Profitability Ratios
MOR's Cumulative Gross Profit Margin
Major Pharmaceutical Preparations Industry Gross Profit Margin Trends and Statistics
Healthcare Sector Gross Profit Margin Statistics
Gross Profit Margin Profitability Trends for overall market
MOR's Gross Profit Margin Profitability versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Gross Profit Margin
Lowest Ranking Gross Profit Margin
Gross Profit Margin Profit Margin for MOR's Competitors
Gross Profit Margin Profit Margin for Morphosys Ag's Suppliers
Gross Profit Margin Profit Margin for MOR's Customers

You may also want to know
MOR's Annual Growth Rates MOR's Profitability Ratios MOR's Asset Turnover Ratio MOR's Dividend Growth
MOR's Roe MOR's Valuation Ratios MOR's Financial Strength Ratios MOR's Gross Profit Growth
MOR's Roa MOR's Inventory Turnover Ratio MOR's Growth Rates MOR's Dividend Comparisons


Companies with similar Gross Profit Margin in the quarter ending Dec 31 2023, within Major Pharmaceutical Preparations Industry Gross Profit MarginDec 31 2023 MRQ Gross ProfitDec 31 2023 MRQ Revenue
Emmaus Life Sciences Inc   102.25 %$ 6.876  Millions$ 6.725  Millions
Therapeuticsmd Inc   100.00 %$ 0.502  Millions$ 0.502  Millions
Carisma Therapeutics Inc   99.74 %$ 4.289  Millions$ 4.300  Millions
Blueprint Medicines Corporation  99.67 %$ 77.516  Millions$ 77.776  Millions
Ionis Pharmaceuticals Inc   99.06 %$ 321.443  Millions$ 324.505  Millions
Corcept Therapeutics Inc  98.61 %$ 133.529  Millions$ 135.405  Millions
Macrogenics Inc   98.48 %$ 10.557  Millions$ 10.720  Millions
Sage Therapeutics Inc   98.28 %$ 76.631  Millions$ 77.971  Millions
Serina Therapeutics Inc   98.21 %$ 0.055  Millions$ 0.056  Millions
Lexaria Bioscience Corp   96.81 %$ 0.146  Millions$ 0.151  Millions
Reshape Lifesciences Inc  96.34 %$ 1.842  Millions$ 1.912  Millions
Deciphera Pharmaceuticals Inc   96.30 %$ 46.509  Millions$ 48.294  Millions
Aclaris Therapeutics Inc   95.87 %$ 16.845  Millions$ 17.570  Millions
Karyopharm Therapeutics Inc   95.60 %$ 32.261  Millions$ 33.747  Millions
Gyre Therapeutics Inc   95.40 %$ 25.898  Millions$ 27.148  Millions
Calliditas Therapeutics Ab  95.36 %$ 123.241  Millions$ 129.241  Millions
Palatin Technologies Inc   95.20 %$ 1.936  Millions$ 2.034  Millions
Lexicon Pharmaceuticals Inc   93.30 %$ 0.655  Millions$ 0.702  Millions
Vanda Pharmaceuticals Inc   92.36 %$ 41.811  Millions$ 45.271  Millions
Acadia Pharmaceuticals Inc   92.26 %$ 213.151  Millions$ 231.041  Millions
Agios Pharmaceuticals Inc   91.75 %$ 6.517  Millions$ 7.103  Millions
Silo Pharma Inc  91.52 %$ 0.017  Millions$ 0.018  Millions
Amylyx Pharmaceuticals Inc   91.37 %$ 99.089  Millions$ 108.449  Millions
Regeneron Pharmaceuticals Inc   91.07 %$ 3,127.500  Millions$ 3,434.300  Millions
Ocular Therapeutix Inc   90.64 %$ 13.416  Millions$ 14.802  Millions
Ultragenyx Pharmaceutical Inc   90.54 %$ 115.341  Millions$ 127.392  Millions
Urogen Pharma Ltd   90.28 %$ 21.244  Millions$ 23.530  Millions
Amicus Therapeutics inc   90.16 %$ 103.758  Millions$ 115.082  Millions
Verrica Pharmaceuticals Inc   89.94 %$ 1.788  Millions$ 1.988  Millions
Pharming Group N v   89.80 %$ 220.104  Millions$ 245.104  Millions




Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.